Candriam Luxembourg S.C.A. Has $5.60 Million Position in Ionis Pharmaceuticals, Inc. (IONS)

Candriam Luxembourg S.C.A. reduced its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 42.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,000 shares of the company’s stock after selling 81,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.09% of Ionis Pharmaceuticals worth $5,596,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IONS. Sei Investments Co. raised its position in Ionis Pharmaceuticals by 27.6% in the second quarter. Sei Investments Co. now owns 51,357 shares of the company’s stock valued at $2,613,000 after buying an additional 11,120 shares during the last quarter. World Asset Management Inc raised its position in Ionis Pharmaceuticals by 3.4% in the second quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock valued at $286,000 after buying an additional 187 shares during the last quarter. Grandfield & Dodd LLC raised its position in Ionis Pharmaceuticals by 5.7% in the second quarter. Grandfield & Dodd LLC now owns 12,809 shares of the company’s stock valued at $652,000 after buying an additional 690 shares during the last quarter. Rothschild Asset Management Inc. raised its position in Ionis Pharmaceuticals by 5.6% in the second quarter. Rothschild Asset Management Inc. now owns 253,642 shares of the company’s stock valued at $12,903,000 after buying an additional 13,520 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Ionis Pharmaceuticals by 5.2% in the second quarter. Janney Montgomery Scott LLC now owns 52,263 shares of the company’s stock valued at $2,659,000 after buying an additional 2,573 shares during the last quarter. 89.08% of the stock is owned by hedge funds and other institutional investors.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up 1.89% during mid-day trading on Wednesday, hitting $47.41. The stock had a trading volume of 965,537 shares. The firm has a market cap of $5.90 billion, a PE ratio of 227.93 and a beta of 3.14. The firm has a 50 day moving average price of $52.04 and a 200 day moving average price of $47.05. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $60.01.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.03. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same period in the prior year, the firm posted ($0.47) EPS. Ionis Pharmaceuticals’s revenue for the quarter was up 170.7% compared to the same quarter last year. Equities analysts predict that Ionis Pharmaceuticals, Inc. will post ($0.11) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at [[permalink]].

Several research analysts recently issued reports on IONS shares. Evercore ISI started coverage on Ionis Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating on the stock. Laidlaw reaffirmed a “buy” rating and set a $65.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday. BMO Capital Markets upped their target price on Ionis Pharmaceuticals from $67.00 to $69.00 and gave the company an “outperform” rating in a research report on Monday. Jefferies Group LLC reaffirmed an “underperform” rating and set a $18.00 target price (up from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Finally, Stifel Nicolaus upped their target price on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a research report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $47.67.

In other news, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $52.10, for a total transaction of $859,650.00. Following the sale, the chairman now owns 51,476 shares of the company’s stock, valued at approximately $2,681,899.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP C Frank Bennett sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the sale, the senior vice president now directly owns 25,041 shares in the company, valued at approximately $1,484,680.89. The disclosure for this sale can be found here. Insiders have sold a total of 54,379 shares of company stock worth $2,946,052 in the last three months. Corporate insiders own 1.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.